Healthy Volunteer

130
Pipeline Programs
30
Companies
50
Clinical Trials
19 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
128
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
943%
Small Molecule
943%
RNA Therapeutic
314%
+ 113 programs with unclassified modality

Competitive Landscape

39 companies ranked by most advanced pipeline stage

Allergy Therapeutics
1
FlucelvaxPhase 21 trial
Active Trials
NCT04025580CompletedEst. Jan 2023
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
TradipitantPhase 1/21 trial
Active Trials
NCT04849559Completed27Est. Sep 2021
Roche
RocheSTAVANGER NORWAY, Norway
21 programs
19
AlectinibPhase 1Small Molecule1 trial
BasmisanilPhase 11 trial
FluvoxaminePhase 11 trial
MidazolamPhase 11 trial
Midazolam, IVPhase 11 trial
+16 more programs
Active Trials
NCT01926873Completed240Est. Jul 2014
NCT00520273Completed100,000Est. Oct 2007
NCT01984229Completed23Est. Mar 2014
+28 more trials
Biogen
BiogenCAMBRIDGE, MA
21 programs
20
AducanumabPhase 1Monoclonal Antibody1 trial
BIIB091Phase 11 trial
BIIB091Phase 11 trial
BIIB091Phase 11 trial
BIIB095Phase 11 trial
+16 more programs
Active Trials
NCT02996084Completed246Est. Dec 2022
NCT05216887Completed123Est. Jul 2022
NCT06574828Completed69Est. Mar 2025
+19 more trials
Genentech
13 programs
13
CobimetinibPhase 1Small Molecule1 trial
CrenezumabPhase 1Monoclonal Antibody1 trial
DSTA4637SPhase 11 trial
EtrolizumabPhase 1Monoclonal Antibody1 trial
GDC-0032Phase 11 trial
+8 more programs
Active Trials
NCT01277718Completed20Est. Feb 2011
NCT02427243Completed60Est. Jul 2015
NCT02596399Completed30Est. May 2016
+10 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
12 programs
12
ABBV-101Phase 11 trial
ABBV-1354Phase 11 trial
ABBV-547Phase 11 trial
ABBV-701Phase 11 trial
ABBV-722Phase 12 trials
+7 more programs
Active Trials
NCT06887010Completed17Est. Sep 2025
NCT07219017Completed8Est. Dec 2025
NCT07232004Recruiting87Est. Sep 2027
+20 more trials
Regeneron
RegeneronTARRYTOWN, NY
8 programs
7
ALN-F1202Phase 11 trial
DupilumabPhase 1Monoclonal Antibody
PozelimabPhase 1Monoclonal Antibody1 trial
REGN5069Phase 11 trial
REGN6490Phase 11 trial
+3 more programs
Active Trials
NCT05546957Completed60Est. Apr 2023
NCT06669234Active Not Recruiting56Est. Jul 2026
NCT04491838Completed40Est. Mar 2021
+6 more trials
Pfizer
PfizerNEW YORK, NY
6 programs
6
PF 06835919Phase 11 trial
PF-02341066Phase 11 trial
PF-06700841Phase 11 trial
Test formulationPhase 11 trial
atirmociclibPhase 1Small Molecule1 trial
+1 more programs
Active Trials
NCT03916406Completed10Est. Jun 2019
NCT01082380Completed6Est. Apr 2010
NCT04260464Completed30Est. May 2022
+3 more trials
Astellas
4 programs
4
ASP1941Phase 11 trial
SetidegrasibPhase 11 trial
YM150Phase 11 trial
YM178Phase 11 trial
Active Trials
NCT01121198Completed84Est. Jul 2007
NCT07395024Recruiting54Est. Jul 2026
NCT01125670Completed24Est. Apr 2010
+1 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
4
AZD6280Phase 11 trial
AZD8529Phase 15 trials
Dapagliflozin/metformin XR FDC 5/500 mgPhase 11 trial
celecoxibPhase 1Small Molecule1 trial
Active Trials
NCT00681317Completed48Est. Jul 2008
NCT00986531Completed59Est. Oct 2011
NCT00921804Completed296Est. May 2010
+5 more trials
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
3
ApremilastPhase 11 trial
DenosumabPhase 1Monoclonal Antibody1 trial
Denosumab CP4Phase 11 trial
Active Trials
NCT01634191Completed36Est. Apr 2012
NCT01869686Completed12Est. Sep 2013
NCT02053753Completed146Est. Aug 2014
Edgewise Therapeutics
3 programs
3
EDG-5506Phase 11 trial
EDG-5506 TabletPhase 11 trial
[14C]-EDG-7500Phase 11 trial
Active Trials
NCT04585464Completed127Est. Dec 2021
NCT05730842Completed15Est. Apr 2023
NCT06738836Completed8Est. Jan 2025
Ionis Pharmaceuticals
3 programs
3
mipomersenPhase 1RNA Therapeutic1 trial
mipomersenPhase 1RNA Therapeutic1 trial
mipomersenPhase 1RNA Therapeutic1 trial
Active Trials
NCT01299298Completed20Est. Apr 2011
NCT01061814Completed84Est. Jun 2010
NCT01414881Completed20Est. Nov 2012
Alumis
AlumisSOUTH SAN FRANCISCO, CA
2 programs
2
A-005Phase 11 trial
ESK-001Phase 11 trial
Active Trials
NCT07442149Completed135Est. Dec 2024
NCT07378579Completed52Est. Aug 2024
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
2 programs
2
ASTX660Phase 11 trial
ASTX660Phase 11 trial
Active Trials
NCT04411030CompletedEst. Aug 2020
NCT04479800CompletedEst. Aug 2020
Atea Pharmaceuticals
2 programs
2
AT-527Phase 11 trial
BemnifosbuvirPhase 1Small Molecule1 trial
Active Trials
NCT05618314CompletedEst. Jun 2024
NCT05724693CompletedEst. Apr 2024
Bristol Myers Squibb
2 programs
2
BMS-986369Phase 11 trial
BMS-986446 IVPhase 11 trial
Active Trials
NCT05350800Completed68Est. May 2023
NCT06955741Completed46Est. Sep 2025
Revolo Biotherapeutics
2 programs
2
IRL201104Phase 11 trial
IRL201104Phase 11 trial
Active Trials
NCT05921591Completed24Est. Sep 2023
NCT04748536Completed18Est. Apr 2021
Nurix Therapeutics
2
NX-5948Phase 11 trial
NX-5948Phase 11 trial
Active Trials
NCT06717269RecruitingEst. Aug 2026
NCT06691828CompletedEst. Dec 2024
Seismic Therapeutic
Seismic TherapeuticMA - Watertown
2 programs
2
S-1117Phase 11 trial
S-4321Phase 11 trial
Active Trials
NCT06828393RecruitingEst. Mar 2026
NCT06877611RecruitingEst. Apr 2026
Sanofi
SanofiPARIS, France
2 programs
2
eliglustat; digoxinPhase 11 trial
plerixaforPhase 11 trial
Active Trials
NCT01357811Completed28Est. Nov 2011
NCT01579149Completed24Est. Feb 2012
argenx
argenxBelgium - Zwijnaarde
1 program
1
ARGX-109Phase 11 trial
Active Trials
NCT06799416Completed40Est. Aug 2025
Autifony Therapeutics
Autifony TherapeuticsUK - Stevenage
1 program
1
AUT00201Phase 11 trial
Active Trials
NCT04158453Completed80Est. Dec 2020
SK Life Science
SK Life ScienceNJ - Paramus
1 program
1
Alprazolam PlaceboPhase 11 trial
Active Trials
NCT03509285CompletedEst. Dec 2017
Insmed
InsmedBRIDGEWATER, NJ
1 program
1
BrensocatibPhase 11 trial
Active Trials
NCT05355935Completed48Est. Oct 2022
Engrail Therapeutics
Engrail TherapeuticsCA - San Diego
1 program
1
ENX-205Phase 11 trial
Active Trials
NCT07253246Recruiting60Est. Apr 2026
GC Biopharma
1 program
1
GC1113Phase 11 trial
Active Trials
NCT01363934CompletedEst. Jul 2012
Biomea Fusion
Biomea FusionSAN CARLOS, CA
1 program
1
IcovamenibPhase 1Small Molecule
Fusion Pharmaceuticals Inc.
1 program
1
IcovamenibPhase 1Small Molecule1 trial
Active Trials
NCT07254286CompletedEst. Jan 2026
PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
1
KX01 ointment 1%Phase 11 trial
Active Trials
NCT05245578CompletedEst. Jan 2022

+9 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BiogenBIIB115
Rochegantenerumab
AbbVieIcalcaprant
RegeneronREGN7508
AbbVieABBV-932
Rochegantenerumab
Allergy TherapeuticsFlucelvax
RocheRO4917838
Rochealeglitazar
AstraZenecaAZD8529
Rochealeglitazar
Vanda PharmaceuticalsTradipitant
AbbVieABBV-722
AbbVieABBV-8736
AstellasSetidegrasib

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 4,565 patients across 50 trials

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Start: Jan 2026Est. completion: May 203230 patients
Phase 3Recruiting
NCT06424236Rochegantenerumab

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Start: Jun 2020Est. completion: Nov 202373 patients
Phase 2/3Terminated

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Start: Feb 2026Est. completion: Nov 2027195 patients
Phase 2Recruiting

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Start: Oct 2025Est. completion: Apr 20271,200 patients
Phase 2Recruiting

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Start: Sep 2025Est. completion: Apr 2027200 patients
Phase 2Recruiting
NCT04592341Rochegantenerumab

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Start: Nov 2020Est. completion: Mar 2023192 patients
Phase 2Terminated

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Start: Oct 2019Est. completion: Jan 2023
Phase 2Completed

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Start: Oct 2017Est. completion: Jun 201812 patients
Phase 2Completed
NCT01043029Rochealeglitazar

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Start: May 2010Est. completion: Jul 2012302 patients
Phase 2Completed

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

Start: Jun 2009Est. completion: May 2010296 patients
Phase 2Completed
NCT00461006Rochealeglitazar

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Start: Jun 2007Est. completion: Sep 2008176 patients
Phase 2Completed

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Start: Feb 2021Est. completion: Sep 202127 patients
Phase 1/2Completed

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Start: Feb 2026Est. completion: Aug 202632 patients
Phase 1Not Yet Recruiting

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

Start: Feb 2026Est. completion: Jun 202640 patients
Phase 1Recruiting

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

Start: Feb 2026Est. completion: Jul 202654 patients
Phase 1Recruiting

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

Start: Jan 2026Est. completion: Mar 202611 patients
Phase 1Active Not Recruiting

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Start: Dec 2025Est. completion: Feb 2027104 patients
Phase 1Recruiting
NCT07297199BiogenOmaveloxolone

A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55

Start: Dec 2025Est. completion: Apr 202670 patients
Phase 1Recruiting

A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes

Start: Nov 2025Est. completion: Nov 202772 patients
Phase 1Recruiting

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

Start: Nov 2025Est. completion: Sep 202787 patients
Phase 1Recruiting
NCT07261371PfizerTest formulation

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

Start: Nov 2025Est. completion: May 202664 patients
Phase 1Recruiting

A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants

Start: Oct 2025Est. completion: Dec 20258 patients
Phase 1Completed

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

Start: Oct 2025Est. completion: Feb 20268 patients
Phase 1Not Yet Recruiting
NCT07215078Pfizeratirmociclib

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Start: Oct 2025Est. completion: Jun 202672 patients
Phase 1Recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

Start: Oct 2025Est. completion: Jun 2026
Phase 1Recruiting

Food Effect Study in Healthy Volunteers

Start: Sep 2025Est. completion: Jan 2026
Phase 1Completed
NCT07149415BiogenOmaveloxolone

A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

Start: Sep 2025Est. completion: Oct 202522 patients
Phase 1Completed

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

Start: Aug 2025Est. completion: Aug 202678 patients
Phase 1Recruiting

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants

Start: Jul 2025Est. completion: Nov 202520 patients
Phase 1Active Not Recruiting

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

Start: May 2025Est. completion: Sep 202546 patients
Phase 1Completed
NCT06937619AbbVieRisankizumab

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

Start: Apr 2025Est. completion: Nov 2025263 patients
Phase 1Completed

A Phase 1 Study of S-4321

Start: Apr 2025Est. completion: Apr 2026
Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

Start: Apr 2025Est. completion: Nov 2026100 patients
Phase 1Active Not Recruiting

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

Start: Mar 2025Est. completion: Sep 202517 patients
Phase 1Completed

ENX-205 SAD/PET Study in Healthy Adults

Start: Mar 2025Est. completion: Apr 202660 patients
Phase 1Recruiting

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

Start: Mar 2025Est. completion: Jul 202656 patients
Phase 1Active Not Recruiting

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

Start: Mar 2025Est. completion: Jan 202672 patients
Phase 1Completed

A Phase 1 Study of S-1117

Start: Mar 2025Est. completion: Mar 2026
Phase 1Recruiting

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Start: Feb 2025Est. completion: Mar 20269 patients
Phase 1Active Not Recruiting
NCT06454721Biogen[89Zr]Zr-DFO-BIIB080

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Start: Jan 2025Est. completion: Mar 20265 patients
Phase 1Active Not Recruiting

A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

Start: Jan 2025Est. completion: Aug 202540 patients
Phase 1Completed
NCT06733675Basilea PharmaceuticaLedaborbactam etzadroxil

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Start: Jan 2025Est. completion: Jun 2026
Phase 1Recruiting

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

Start: Jan 2025Est. completion: Apr 2026404 patients
Phase 1Active Not Recruiting

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

Start: Dec 2024Est. completion: Jan 20258 patients
Phase 1Completed

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

Start: Dec 2024Est. completion: Jan 20250
Phase 1Withdrawn

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Start: Nov 2024Est. completion: Aug 2026
Phase 1Recruiting

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

Start: Nov 2024Est. completion: Jan 202516 patients
Phase 1Completed

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

Start: Nov 2024Est. completion: Jan 202512 patients
Phase 1Completed

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Start: Nov 2024Est. completion: Dec 2024
Phase 1Completed
NCT06612879BiogenOmaveloxolone

A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk

Start: Oct 2024Est. completion: Apr 202512 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

19 actively recruiting trials targeting 4,565 patients
30 companies competing in this space